Published in Asian J Androl on January 28, 2013
Prognostic value of miR-21 in various cancers: an updating meta-analysis. PLoS One (2014) 0.93
MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. Am J Clin Exp Urol (2014) 0.86
The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells. Asian J Androl (2013) 0.85
Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate (2014) 0.82
The roles of microRNAs in the progression of castration-resistant prostate cancer. J Hum Genet (2016) 0.78
miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Transl Oncol (2016) 0.78
Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One (2014) 0.76
miRNAs associated with prostate cancer risk and progression. BMC Urol (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes (2009) 3.02
MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2008) 2.43
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
A role of miR-27 in the regulation of adipogenesis. FEBS J (2009) 2.27
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2011) 2.19
MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One (2011) 1.90
miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol (2012) 1.81
Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate (2010) 1.81
Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer (2010) 1.76
miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol (2010) 1.75
Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS One (2012) 1.41
Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene (2012) 1.40
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J (2011) 1.39
Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate (2012) 1.39
The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (2010) 1.28
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer (2006) 1.26
Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol (2011) 1.24
MicroRNAs in adipogenesis and as therapeutic targets for obesity. Expert Opin Ther Targets (2011) 1.22
Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol (2006) 1.16
Targeting microRNAs in obesity. Expert Opin Ther Targets (2009) 1.14
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene (2012) 1.13
MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol (2011) 1.12
MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One (2012) 1.11
Gene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity. BMC Endocr Disord (2011) 1.08
MicroRNA 21 regulates the proliferation of human adipose tissue-derived mesenchymal stem cells and high-fat diet-induced obesity alters microRNA 21 expression in white adipose tissues. J Cell Physiol (2012) 1.06
Expression of adipose microRNAs is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS One (2010) 1.02
Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem (2010) 1.01
Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation. Asian J Androl (2012) 0.95
miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol (2011) 0.93
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment. Am J Pathol (2011) 0.87
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol (2008) 1.67
Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer (2005) 1.65
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol (2009) 1.55
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev (2006) 1.45
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Production of interleukin-8 by human neutrophils stimulated with Trichomonas vaginalis. Infect Immun (2004) 1.26
Advantages of Single-Molecule Real-Time Sequencing in High-GC Content Genomes. PLoS One (2013) 1.18
Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology (2004) 1.17
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res (2011) 1.17
The specific role of isoflavones in reducing prostate cancer risk. Prostate (2004) 1.16
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol (2006) 1.09
Genome sequence of Janthinobacterium sp. strain PAMC 25724, isolated from alpine glacier cryoconite. J Bacteriol (2012) 1.08
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer (2011) 1.08
Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol (2003) 1.08
Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol Res (2009) 1.07
Re: "Chylous ascites: analysis of 24 patients". Gynecol Oncol (2012) 1.07
The anti-inflammatory and anti-nociceptive effects of ethyl acetate fraction of cynanchi paniculati radix. Biol Pharm Bull (2006) 1.07
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol (2003) 1.03
Single-port laparoscopic salpingectomy for the surgical treatment of ectopic pregnancy. J Minim Invasive Gynecol (2009) 1.02
The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol (2010) 1.02
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res (2011) 1.01
Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol (2004) 1.00
In Vitro and In Vivo Antibacterial Activity of Punica granatum Peel Ethanol Extract against Salmonella. Evid Based Complement Alternat Med (2011) 0.99
A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer (2007) 0.99
Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol (2010) 0.99
Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol (2008) 0.99
Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis (2011) 0.98
Squamous cell carcinoma and osteosarcoma arising from a dermoid cyst--a case report and review of literature. Int J Clin Exp Pathol (2010) 0.97
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer (2004) 0.97
Primary mixed lymphoepithelioma-like carcinoma and intra-hepatic cholangiocarcinoma: a case report and review of literature. Int J Clin Exp Pathol (2010) 0.96
Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer (2014) 0.96
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol (2002) 0.96
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol (2013) 0.96
Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev (2007) 0.95
Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology (2007) 0.95
The effects of mindfulness-based stress reduction on objective and subjective sleep parameters in women with breast cancer: a randomized controlled trial. Psychooncology (2014) 0.95
Antimalarial activity of lavandulyl flavanones isolated from the roots of Sophora flavescens. Biol Pharm Bull (2004) 0.94
Angiogenin induces nitric oxide synthesis in endothelial cells through PI-3 and Akt kinases. Biochemistry (2010) 0.94
Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol (2010) 0.94
MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol (2011) 0.93
WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis (2011) 0.93
Telomere length in myelodysplastic syndromes. Leuk Lymphoma (2011) 0.93
Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun (2012) 0.93
Anti-inflammatory effects of sulfuretin from Rhus verniciflua Stokes via the induction of heme oxygenase-1 expression in murine macrophages. Int Immunopharmacol (2010) 0.92
Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer (2009) 0.92
Cloning and characterization of a new cysteine proteinase secreted by Paragonimus westermani adult worms. Am J Trop Med Hyg (2004) 0.91
Cerebral metastasis of cervical cancer, report of two cases and review of the literature. Int J Clin Exp Pathol (2012) 0.91
Protective effect of sauchinone by upregulating heme oxygenase-1 via the P38 MAPK and Nrf2/ARE pathways in HepG2 cells. Planta Med (2009) 0.90
An extracellular ice-binding glycoprotein from an Arctic psychrophilic yeast. Cryobiology (2010) 0.90
Change in gene abundance in the nitrogen biogeochemical cycle with temperature and nitrogen addition in Antarctic soils. Res Microbiol (2011) 0.90
Phylogenetic relationships of Korean Sparassis latifolia based on morphological and ITS rDNA characteristics. J Microbiol (2013) 0.89
Short-term results of magnetic resonance imaging-guided focused ultrasound surgery for patients with adenomyosis: symptomatic relief and pain reduction. Fertil Steril (2011) 0.89
Efficacy of the merozoite surface protein 1 of Plasmodium vivax as an antigen for ELISA to diagnose malaria. Yonsei Med J (2004) 0.89
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol (2012) 0.89
Octreotide therapy for the management of refractory chylous ascites after a staging operation for endometrial adenocarcinoma. J Obstet Gynaecol Res (2013) 0.88
In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. J Clin Virol (2007) 0.88
The effect of operative hysteroscopy conducted before progestin treatment in early stage endometrial cancer from the view of fertility. Gynecol Oncol (2011) 0.88
Analysis of protein-protein interactions by using droplet-based microfluidics. Chembiochem (2009) 0.88
High-throughput analysis of protein-protein interactions in picoliter-volume droplets using fluorescence polarization. Anal Chem (2012) 0.88
SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness. PLoS One (2013) 0.88
Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients. Cancer Epidemiol Biomarkers Prev (2004) 0.88
Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother (2008) 0.88
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
In vitro activity of methyl gallate isolated from galla rhois alone and in combination with ciprofloxacin against clinical isolates of salmonella. J Microbiol Biotechnol (2008) 0.87
Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer (2008) 0.87
Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urol (2009) 0.87
Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control (2008) 0.87
Transcriptomics and comparative analysis of three antarctic notothenioid fishes. PLoS One (2012) 0.87
Asiatic acid induces colon cancer cell growth inhibition and apoptosis through mitochondrial death cascade. Biol Pharm Bull (2009) 0.87
Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro. Exp Parasitol (2008) 0.87
Evaluation of the methicillin-resistant Staphylococcus aureus (MRSA)-Screen latex agglutination test for detection of MRSA of animal origin. J Clin Microbiol (2004) 0.87
CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol (2010) 0.86
Accuracy of intraoperative imprint cytology for sentinel lymph node evaluation in the treatment of breast carcinoma. Cancer (2005) 0.86
Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations. Int J Gynecol Cancer (2015) 0.86
Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer (2007) 0.86
Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol (2005) 0.86
Caenorhabditis elegans calnexin is N-glycosylated and required for stress response. Biochem Biophys Res Commun (2005) 0.86
Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials (2011) 0.86
Detection of sentinel lymph nodes in patients with early stage cervical cancer. J Korean Med Sci (2007) 0.86
Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis (2012) 0.85
Development and evaluation of an immunochromatographic kit for the detection of antibody to Plasmodium vivax infection in South Korea. Yonsei Med J (2003) 0.85
Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic. J Biochem (2006) 0.85
Antibacterial activity of medicinal herb extracts against Salmonella. Int J Food Microbiol (2006) 0.85
Inherited variation in the PARP1 gene and survival from melanoma. Int J Cancer (2014) 0.85
Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol (2010) 0.84
Anti-nociceptive and anti-inflammatory effects of Angelicae dahuricae radix through inhibition of the expression of inducible nitric oxide synthase and NO production. Am J Chin Med (2008) 0.84
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res (2013) 0.84